

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Tissue-specific and spatially dependent metabolic signatures perturbed by injury in skeletally mature male and female mice

Authors

Hope D. Welhaven¹, Avery H. Welfley², Priyanka P. Brahmachary², Donald F. Smith¹, Brian Bothner¹, Ronald K. June^{2*}

Affiliations

¹Department of Chemistry & Biochemistry, Montana State University, Bozeman MT.

²Department of Mechanical & Industrial Engineering, Montana State University, Bozeman MT.

***Corresponding Author**

*Ronald K. June, Ph.D.

Department of Mechanical & Industrial Engineering, Montana State University

PO Box 173800, Bozeman, MT 59717-3800 | Phone: (406) 994-5941; Fax: (406) 994-6292; E-mail: rjune@montana.edu

Keywords: osteoarthritis, sex differences, metabolomics, MALDI imaging

24 **Abstract**

25 Joint injury is a risk factor for post-traumatic osteoarthritis. However, metabolic and
26 microarchitectural changes within the joint post-injury in both sexes remain unexplored. This study
27 identified tissue-specific and spatially-dependent metabolic signatures in male and female mice
28 using matrix-assisted laser desorption ionization-mass spectrometry imaging (MALDI-MSI) and
29 LC-MS metabolomics. Male and female C57Bl/6J mice were subjected to non-invasive joint injury.
30 Eight days post-injury, serum, synovial fluid, and whole joints were collected for metabolomics.
31 Analyses compared between injured, contralateral, and naïve mice, revealing local and systemic
32 responses. Data indicate sex influences metabolic profiles across all tissues, particularly amino
33 acid, purine, and pyrimidine metabolism. MALDI-MSI generated 2D ion images of bone, the joint
34 interface, and bone marrow, highlighting increased lipid species in injured limbs, suggesting
35 physiological changes across injured joints at metabolic and spatial levels. Together, these
36 findings reveal significant metabolic changes after injury, with notable sex differences.

37 **Significance statement:**

38 Osteoarthritis, the leading cause of disability worldwide, disproportionately affects females
39 with sex being one of the strongest predictors of disease. This disparity is partly driven by sex-
40 specific differences in injury susceptibility, increasing the likelihood of traumatic injury to the
41 anterior cruciate ligament (ACL), other ligaments, and menisci. Using a non-invasive injury model,
42 we demonstrate that injury perturbs the local joint environment and has systemic effects in a sex-
43 specific manner. Furthermore, by leveraging matrix-assisted laser desorption ionization-mass
44 spectrometry imaging of the joint, we provide new insight into the composition of osteochondral
45 tissue at the metabolite level. These sexually dimorphic metabolic responses to joint injury
46 advance current understanding of the complex sexual dimorphism in OA pathogenesis providing
47 a foundation for targeted therapeutic strategies and improved patient outcomes for female
48 patients.
49

50 **Introduction**

51 Post-traumatic osteoarthritis (PTOA) accounts for 12% of osteoarthritis (OA) cases,
52 resulting in at least 5.6 million cases annually[1, 2]. The most prevalent risk factor for PTOA is
53 joint injury. 250,000 anterior cruciate ligament (ACL) injuries occur annually, commonly in young
54 individuals aged 16-24. Upwards of 50% of patients will develop PTOA within 10-20 years of
55 injury[3-6]. Furthermore, female sex is a risk factor for joint injury: young female athletes are 2-8
56 times more likely to sustain a traumatic knee injury requiring surgical repair compared to males[7,
57 8]. Later in life, females are more likely to develop OA and typically experience greater symptom
58 severity[9, 10]. Sexual dimorphism in PTOA development may partially result from hormonal and
59 anatomical differences including females have wider pelves, smaller femurs, different muscle
60 angles, and physically smaller ACLs[11, 12]. Despite these empirical sex differences, many
61 studies fail to include both female and male subjects.
62

63 While injury and sex are well-known PTOA risk factors, underlying mechanisms and
64 changes in joint metabolism and microarchitecture following injury remain incompletely
65 understood. Metabolomics—the study of small molecule intermediates called metabolites—
66 captures the physiological and metabolic status of the joint. While synovial fluid (SF) and serum
67 are assessed post-injury in human and mouse models[13-17], metabolomics can also be applied
68 to whole joint tissue to characterize metabolic changes occurring in bone and cartilage post-injury.
69 This approach combined with spatial imaging through matrix-assisted laser desorption ionization-
70 mass spectrometry imaging (MALDI-MSI) provides critical unknown spatial context of
71 osteochondral tissues at the metabolite level. Few studies report spatial data involving

72 musculoskeletal tissues such as cartilage[21, 22] and synovium[23]. However, no study to date
73 has utilized MALDI-MSI to characterize molecular changes between male and female injured and
74 naïve mice.

75 Therefore, the first objective of this study was to characterize metabolomic differences
76 within and across whole joints, SF, and serum from injured and naïve male and female mice using
77 liquid chromatography-mass spectrometry (LC-MS) metabolomics. Investigating differences in
78 metabolism in different tissues and between injured, contralateral, and naïve limbs is important to
79 shed light on both local and systemic metabolic responses following injury. The second objective
80 was to spatially locate and identify osteochondral metabolites using MALDI-MSI. By combining
81 untargeted metabolomic profiling and MALDI-MSI, we can pinpoint the origin of metabolic and
82 pathological shifts and gain a better understanding of the effects of injury and sex on the joint as
83 a whole.

84

85 **Results**

86

87 **Injury Perturbs the Metabolome Systemically Across Injured and Naïve Whole Joints, 88 Synovial Fluid, and Serum**

89 In total, 2,769 metabolite features were detected across all samples (n=92). Whole joints,
90 SF, and serum were assessed among all samples and injured samples only revealing distinct
91 metabolomic profiles between tissues and fluids as showcased by PLS-DA (Fig. S1A-B). ANOVA
92 found 2,264 and 1,891 metabolite features that were significantly dysregulated across all samples
93 and only injured samples, respectively (Fig. S1C-D). Next, we assessed metabolic patterns
94 associated with injury within each sample type. PLS-DA assessed metabolomic profiles by injury
95 status across whole joint, SF, and serum (Fig. 1A-C). Fold change analysis identified populations
96 of metabolite features driving these differences between injury groups, which were subjected to
97 pathway analysis (Fig. 1D-F). Comparing injured and naïve whole joints, 7 pathways were
98 dysregulated. Pantothenate/CoA biosynthesis and histidine metabolism were highest in injured
99 whole joints (Table S1A). In SF, 12 pathways were dysregulated: arginine and proline metabolism,
100 lysine degradation, and glutathione metabolism were highest in injured SF (Table S1B). Features
101 highest in serum from injured mice mapped to various amino acid pathways, including arginine
102 and proline metabolism, nucleotide pathways, vitamin, and glutathione metabolism (Table S1C).
103 Next, metabolic indicators of injury were assessed using volcano plot analyses, comparing
104 features differentially regulated across injured and naïve samples (Fig. S2A-C). Cross-referencing
105 these features with LC-MS/MS data identified 3,4-Dimethyl-5-pentyl-2-furanundecanoic acid as
106 differentially regulated between naïve and injured whole joints, while numerous amino acid
107 metabolites, such as D/L-glutamine, were higher in injured SF compared to naïve (Table S2).

108 Next, metabolic differences associated with injured, contralateral, and naïve whole joints and
109 SF were examined. PLS-DA analysis of all three joint types revealed overlap, where the
110 metabolome of injured whole joints and SF resides between contralateral and naïve whole joints
111 and SF (Fig. 1G, H), suggesting metabolic differences associated with injury at the whole joint
112 and SF levels are observed in the contralateral limb. Metabolite features that are co-regulated
113 and differentially expressed across whole joints and SF were clustered using heatmaps of median
114 metabolite feature intensities, which were then subjected to pathway analyses (Fig. 1I, J).
115 Comparing injured, contralateral, and naïve whole joints 22 pathways were detected and 24
116 among SF (Table S3, S4). A handful of pathways were detected in both heatmaps. Amino acid
117 pathways – alanine, aspartate, and glutamate metabolism; arginine and proline metabolism,
118 lysine degradation – were higher in injured and contralateral whole joints and lower in these same
119 groups in SF, compared to naïve controls. Notably, glutathione metabolism was consistently

120 highest in injured whole joints and SF compared to contralateral and naïve controls. Purine and
121 pyrimidine metabolic pathways also displayed a similar pattern where these pathways were
122 highest in injured whole joints and SF. These systemic injury-induced effects across limbs in
123 whole joints and SF were examined through pairwise comparisons and are discussed in detail in
124 the supplemental results (Figs. S3-4, Tables S5-6). Notably, unloaded contralateral limbs
125 resembled injured more than naïve limbs, further supporting that injury perturbs beyond the site
126 of injury, and instead has clear systemic effects.

127
128

Sex Influences Metabolomic Profiles Across Tissues of Injured and Naive Mice

129 To examine the effects of sex and its interactions with injury, pairwise comparisons were
130 performed. First, general sex differences were examined in whole joints (Fig. S5), revealing
131 distinct sex-dependent metabolomic profiles. Then, whole joints from injured males and females
132 were assessed using PLS-DA finding clear separation of mice within their respective cohorts.
133 Differences due to injury are evident when comparing whole joints from injured and naïve females
134 and from injured and naïve males as seen by minimal PLS-DA overlap (Fig. 2A-C). This same
135 pattern was evident in both SF (Fig. 2G-I) and serum (Fig. 2M-O), with serum differences being
136 the most drastic among samples. These findings at the molecular level demonstrate that sex-
137 specific differences emerge post-injury, are more pronounced within the serum, and contribute to
138 the mounting evidence indicating the role of sex in PTOA development.

139 Fold change analysis found populations of metabolite features from whole joints, SF, and
140 serum that show distinct injury- and sex-specific pathways with many conserved across all three
141 sample types (Tables S7-9). Alanine, aspartate, and glutamate metabolism were detected in
142 whole joints of injured males and SF and serum of both injured males and females. Arginine
143 biosynthesis was detected among whole joints from males; however, it was also detected in
144 serum from injured females and SF from injured males and females. Beta-alanine, glyoxylate,
145 and dicarboxylate metabolism were detected across all male naïve tissues. Cysteine and
146 methionine metabolism was detected in both whole joint and SF from injured females.
147 Interestingly, lysine degradation and pyrimidine metabolism were detected across all three
148 sample types in injured females. Notably, glycerophospholipid metabolism was continually
149 associated with injury, and was highest in samples from injured males at the whole joint and
150 serum levels, whereas it was highest in SF from injured females.

151 To investigate metabolic indicators of both injury and sex, volcano plot analysis was
152 performed comparing whole joints, SF, and serum from injured and naïve males and females.
153 This identified sex- and injury-specific metabolites, including those linked to terpenoid backbone
154 biosynthesis – (6R)-6-(L-Erythro-1,2-Dihydroxypropyl)-5,6,7,8-tetrahydro-4a-hydroxypterin in
155 females and Sterebin E in males – in whole joints. Additionally, 1/3-Methylhistamine and valine
156 showed similar patterns across SF and serum, with valine associated with males, and highest in
157 injured males. Notably, 1/3-methylhistidine was associated with injury, regardless of sex, and was
158 highest in SF from injured females (Figure S6, Table S2).

MALDI-MSI Spatially Locates and Detects Differences in Osteochondral Metabolites

160 MALDI-MSI was used to characterize metabolites that are tissue-specific in the whole
161 joint. A novel protocol for sample preparation, matrix application, and instrumentation was
162 developed to examine spatial changes. Using unsupervised segmentation, discriminating
163 features from different spatial areas of the joint were clustered together. When comparing spatial
164 distributions of ions belonging to the bone and joint interface against the bone marrow, numerous

165 features had area under the curve (AUC) values greater than 0.6 (n=37) and 0.8 (n=21),
166 demonstrating tissue-dependent metabolite signatures. Using LC-MS/MS-derived metabolite
167 identifications from whole joint samples, a handful of these metabolites with unique spatial
168 patterns were putatively identified. Those with notable spatial patterns in bone included alpha-
169 carboxy-delta-decalactone (215.20 m/z, AUC = 0.838), hydroxyprolyl-isoleucine (245.11 m/z,
170 AUC = 0.859), and C₃₆H₃₈O₇ (629.61 m/z, AUC = 0.829) (Fig. 3, Fig. S7A, Table S10A).
171 Conversely, metabolites with notable patterns among bone marrow included carnitine (162.29
172 m/z, AUC = 0.821) and various phosphatidylcholine lipid species (34 carbons, 2 double bonds –
173 758.57 m/z, AUC = 0.731; 34 carbons bonds, 3 double bonds – 778.59 m/z, AUC = 0.856; 39
174 carbons, 6 double bonds – 820.41 m/z, AUC = 0.866) (Fig. 3, Fig. S7B, Table S10A). Many
175 metabolites displayed unique spatial patterns between bone, the joint interface, and bone marrow
176 but were unable to be identified. However, many of these were within the common lipid m/z range
177 (400-800 m/z) (Fig. S8, Table S10B).

178 To investigate injury-associated spatial patterns, ion images from medial and lateral
179 aspects of both injured and contralateral mouse joints were examined. In an injured joint, the
180 metabolite feature 544.41 m/z and the putatively identified metabolite—a PC with 36 carbons, 6
181 double bonds 878.54 m/z—display notable injury-associated patterns between medial and lateral
182 sagittal sections where they are more abundant in the injured joint compared to the contralateral
183 joint (Fig. S9). Sex-associated patterns were not examined at length due to the limited number of
184 joints allocated for MALDI-MSI (n = 1 mouse/group, n = 2 males, 2 females, n = 4 mice total).

185 186 **Discussion**

187 To our knowledge, this is the first study to comprehensively examine structural and
188 metabolic responses following injury both locally (whole joints and SF) and systemically (serum)
189 across males and females using LC-MS metabolomic profiling and MALDI-MSI. Our findings
190 reveal significant metabolic and pathologic shifts following joint injury, with discernable sex-
191 specific associations. By uncovering novel metabolic differences linked to these key PTOA risk
192 factors across multiple sample types and biological scales, our study advances the understanding
193 of post-injury responses beyond the joint. These insights provide critical, and previously unknown,
194 context on the joint-specific metabolic and systemic changes that shape disease progression.

195 196 **Effects of injury across whole joints, synovial fluid, and serum**

197 Distinct metabolomic profiles of whole joints, SF, and serum reveal acute changes in
198 response to injury. Various amino acid pathways exhibit differential regulation across tissues with
199 many overlapping between tissues. Lysine degradation was differentially regulated across
200 injured, contralateral, and naïve whole joints while being downregulated in SF contralateral and
201 injured limbs (versus naïve). This may relate to collagen, where hydroxylation of lysine residues
202 is crucial for structural integrity crosslinking [25]. In bone, collagen is a major component of the
203 structural organic matrix. Alteration of lysyl hydroxylase in osteoblasts yields defective cross-
204 linking, fibrillogenesis, and matrix mineralization[25-27] underscoring the importance of lysine
205 hydroxylation in bone quality. In SF, lysine metabolism decreases as OA progresses[28],
206 suggesting this pathway could represent acute joint changes following injury that could be
207 monitored during disease progression.

208 Arginine and proline metabolism was upregulated in naïve whole joints and in injured SF.
209 Like lysine, proline can strengthen collagen crosslinks through hydroxyproline modification.
210 Arginine has anti-inflammatory effects and decreases as OA develops[29, 30]. Arginine and
211 proline metabolism increase in rabbit SF post-ACL injury[31], in human SF after knee injuries[32],

212 and in mouse serum 1-day post-ACL injury[15]. Combined, this suggest a short-term protective
213 mechanism, or cascade of pathways to enhance collagen production post-injury.

214 Phenylalanine, tyrosine, and tryptophan biosynthesis exhibited differential regulation
215 between injured, contralateral, and naïve limbs in whole joint samples and SF. While higher in
216 injured and contralateral whole joints (versus naïve), these pathways showed the opposite trend
217 in SF. Calcium-sensing receptors preferentially bind these aromatic amino acids, leading to a rise
218 in intracellular calcium and modulation of bone turnover[33, 34]. Moreover, phenylalanine and
219 tyrosine metabolism are associated with the sclerosis of subchondral bone in OA[35]. In a
220 noninvasive mouse injury model, tryptophan metabolism was higher in mouse SF 7 days post-
221 injury compared to naïve controls. Tryptophan has been noted as a promising OA biomarker with
222 decreases as disease progresses[36, 37]. Our detection of this pathway in both injured and
223 contralateral whole joints is novel, suggesting a systemic response in both injured and
224 contralateral whole joints. Moreover, these results hold promise as amino acids play a role in the
225 response to acute injury[38], are detected post-injury across mammalian models[15, 16, 31], and
226 change concentration with disease progression.

227

228 **Sexual dimorphism of injury among the metabolome of whole joints, synovial fluid, and** 229 **serum**

230 Considering both injury and sex, purine and pyrimidine metabolism—used for nucleotide
231 synthesis—were dysregulated. Purine metabolism was consistently detected across all tissues
232 from injured males, particularly in serum, which likely results from increased uric acid—an end
233 product of purine metabolism—in male[39] (because female hormones decrease uric acid
234 levels[40]). Conversely, pyrimidine metabolism was dominant in tissues from injured females,
235 necessitating further research to understand its sexual dimorphic regulation.

236 Dysregulated glycine, serine, and threonine metabolism was detected in serum and SF in
237 injured males and females. This pathway was notably perturbed among female sheep post-ACL
238 injury, with serine suggested as a biomarker for early degenerative changes[14]. Serine, a
239 glucogenic amino acid, influences adenosine monophosphate kinase (AMPK), which acts as a
240 key “energy sensor” that maintains energy homeostasis and promotes ATP synthesis via
241 serine/threonine phosphorylation[41-43]. Enzymes like AMPK are differentially influenced by
242 circulating sex hormones like estrogen, which can bind to estrogen receptor beta, triggering
243 downstream metabolic cascades to generate ATP[44, 45]. The influence of circulating sex
244 hormones, like estrogen, on AMPK activity may affect energy metabolism post-injury, warranting
245 further investigation into sexual dimorphic patterns.

246 Cysteine and methionine metabolism was detected in whole joints and SF from injured
247 females but also in serum from injured males. Histidine metabolism was most dysregulated in
248 injured males in serum and whole joints and in injured females SF. These three amino acids relate
249 to matrix metalloproteinase (MMP) regulation of tissue remodeling and degradation of
250 extracellular matrix proteins, cell proliferation, and immune responses[46]. MMP activation is
251 modulated by a cysteine switch, and the catalytic domain of MMPs is regulated by these amino
252 acids because zinc binds to histidines with assistance from conserved methionine sequences[46,
253 47]. MMP activity is influenced by hormones[48], like estrogen and progesterone, particularly in
254 chondrocytes. Postmenopausal OA chondrocytes cultured with 17 β -estradiol found that
255 physiological levels of estrogen suppressed the expression of MMP-1 and that hormone
256 replacements might benefit female OA patients in the early stages of disease[49]. Thus,
257 differential regulation of AMPK and MMP-associated amino acids between males and females
258 post-injury suggests reliance on different metabolic pools, mechanisms, and biofuels to meet
259 energy demands and maintain matrix properties following joint injury.

260 **MALDI-MSI Provides New Insight into Composition of Osteochondral Tissue at the**
261 **Metabolite Level**

262 To our knowledge, this is the first study to provide critical unknown spatial context of
263 osteochondral tissues at the metabolite level, and after joint injury. We developed an innovative
264 protocol to spatially characterize osteochondral metabolites from whole joints of injured and naïve
265 mice using MALDI-MSI. Few studies have employed MALDI-MSI in musculoskeletal tissues to
266 visualize the spatial distribution of proteins and peptides[20, 23, 28, 50]. Traditionally, histological
267 sectioning and imaging of whole joints—and bone samples in general—require formalin fixation
268 and paraffin embedding to preserve and demineralize the bone; however, this results in removal,
269 cross-linking, and/or delocalization of molecular species, especially lipids[24], leading us to
270 develop this novel protocol to examine spatial metabolite distributions.

271 Lipid metabolism is increasingly recognized in the development of PTOA and OA.
272 Proteomic and metabolomic studies demonstrate an important relationship between OA and lipid
273 metabolism in samples of SF, cartilage, bone, and circulatory fluids from both humans and
274 mice[21, 28, 51-54]. Employing MALDI-MSI to target small molecules (50-1500 m/z) provides
275 novel insight into joint composition, lipid dynamics, and changes post-injury. We successfully
276 mapped differences in injury-related osteochondral metabolites, where many were lipids. These
277 findings align with metabolomic assessments finding lipid-associated pathways—such as
278 glycerophospholipid metabolism—higher in injured joints compared to naïve and contralateral
279 joints. Consistent with our previous analysis of metabolic endotypes of early PTOA in SF[17, 28,
280 32, 50] and in OA cartilage[54, 55], dysregulated lipid metabolism is linked to both early-stage
281 PTOA and end-stage OA, suggesting similar metabolic shifts occur in the joint at the metabolic
282 and spatial levels. This underscores the need for further research into lipid metabolism's role in
283 both local and systemic changes following injury and during early PTOA. This two-pronged
284 approach utilizing LC-MS-based metabolomics and MALDI-MSI sheds light on the importance of
285 lipids in joint metabolism, both systemically and intra-articularly. Moving forward, MALDI-MSI
286 across proteins and metabolites can be leveraged and integrated with existing techniques to
287 enhance our understanding of the joint's post-injury response across multiple tissues.

288 Our study has limitations. Firstly, we focused on the early response to joint injury where
289 mice were euthanized 8 days post-injury. Additional time points both within the first 7 days post-
290 injury as well as longer[56] may shed light on the trajectory of structural and metabolic changes
291 across serum, SF, and whole joints. Secondly, metabolite extraction protocols and use of HILIC
292 column bias data toward the assessment of polar molecules. Moreover, DHB was used for
293 MALDI-MSI, which is optimal for positive ionization mode. Combined, LC-MS and MALDI-MSI
294 analyses were both conducted in positive ionization mode focusing on polar molecules, thus
295 additional investigation into nonpolar species is warranted.

296
297 **Conclusions**

298 The findings of our study, integrating LC-MS-based metabolomics and MALDI-MSI,
299 underscore significant metabolic and pathological shifts following joint injury, with discernible sex-
300 specific associations. The detection of novel differences associated with both injury and sex
301 across serum, SF, and whole joints expands our current understanding of the post-injury response
302 within and beyond the joint. Moreover, these data show that injury drives whole joint
303 pathophysiology across multiple tissues. Further, differences in the SF metabolome compared to
304 naïve animals show that the systemic response extends to both injured and contralateral joints.
305 Comprehensive investigation into spatial and sex-dependent molecular changes driven by injury,
306 at the systemic, joint, and synovial fluid levels, is imperative for a deeper understanding of the

307 effects of injury. Extension of these studies may improve pre-clinical PTOA models and deepen
308 our insights into PTOA development, thereby advancing strategies for prevention and treatment.

309

310 **Materials and Methods**

311

312 **Animals**

313 C57Bl/6J mice (N=20, n = 10 female, n = 10 male) were purchased from Charles River
314 Laboratories at 18 weeks of age and acclimated to the Montana State University (MSU) Animal
315 Research Center for 3 weeks. Mice were housed in cages of 3-5 animals and fed standard chow
316 *ad libitum* (PicoLab Rodent Diet 20, 20% protein). All animal procedures were approved by the
317 MSU IACUC.

318 **Joint Injury Model and Experimental Design**

319 21-week-old mice were randomly assigned to experimental groups: injured or non-injured.
320 The injury group were subjected to a non-invasive compressive overload model where the ACL
321 is ruptured similar to human ACL tears, an injury associated with degeneration of bone and
322 cartilage (target force = 12N, loading rate = 130 mm/s) [57, 58]. ACL injury was confirmed by
323 laxity tests. After 8 days, mice were euthanized and whole joints, SF, and serum were harvested.
324 Serum samples were obtained by cardiac puncture and prepared as previously described[59]. SF
325 was recovered and then extracted using established protocols[60], with some modifications where
326 Whatman paper (Sigma, WHA1441042) was used to absorb SF. Whole joints were harvested,
327 and all soft tissue was removed.

328

329 **Metabolomics**

330

331

Metabolite Extraction and Mass Spectrometry Instrumentation

332 Whole joints, SF, and serum were extracted and analyzed using validated protocols with
333 slight modifications[32]. Whole joints were disarticulated to separate the tibia and femur where
334 both were trimmed, centrifuged to remove bone marrow, and homogenized in 1 mL of 80:20
335 methanol:H₂O (1200 GenoLyte, Fischer Scientific). This same extraction solvent was added to
336 serum and SF, followed by vortexing. All samples were chilled overnight at -20°C. The next day,
337 samples were removed from -20°C, centrifuged, and supernatant was dried via vacuum
338 concentration. To remove any remaining proteins, lipids, and waxes, dried extracts were
339 resuspended with 250 μ L of 1:1 acetonitrile:H₂O, vortexed, chilled at -20°C for 30 minutes, and
340 centrifuged again. Supernatant was dried once more, and extracts were prepped for LC-MS using
341 100 μ L of 1:1 acetonitrile:water. Additionally, pooled samples were generated by randomly pooling
342 a total of 50 μ L for each tissue type (n=4/tissue). Pooled samples from each tissue type were also
343 pooled for identification purposes. All solvents used were LC-MS grade (Fischer Scientific).
344 Extracted samples and pools were analyzed via LC-MS as previously described[32].

345

Metabolite Profiling and Identification

346 All LC-MS data—mass-to-charge ratios (m/z), relative metabolite abundance, and
347 retention time—were processed using MSConvert and Progenesis QI (Table S11). Statistical and
348 pathway analyses were performed in MetaboAnalyst (version 6.0)[61]. Significance for statistical
349 and pathway analyses was determined using a FDR-corrected significance level of $p < 0.05$.

350

351

352

353

LC-MS/MS data derived from pooled samples were analyzed within Progenesis QI where
acquired fragmentation patterns were matched against theoretical fragmentation patterns to
identify metabolites[32]. Those identified were matched against populations of LC-MS-based
features distinguished by statistical analyses to discover potential metabolic indicators of disease

354 as well as sexually dimorphic metabolites. To minimize false identifications when comparing LC-
355 MS and LC-MS/MS metabolite features and identifications, a tolerance level of 10 parts per million
356 was enforced.

357

358 **Matrix-Assisted Laser Desorption Ionization Imaging**

359 **Sample Preparation**

360 Whole joints selected for MALDI-MSI (n = 1 mouse/group, n = 2 joints/mouse) were
361 removed from -80°C and prepped according to the novel protocol developed for whole joint
362 sectioning and imaging (Fig. S10). Whole joints were embedded using warm 5%
363 carboxymethylcellulose sodium salt (ThermoFischer, A18105-36) and 10% gelatin (Thermo
364 Scientific, AC611995000)[24, 62]. Note that OCT media is incompatible with mass spectrometry
365 analysis due to the presence of polyethylene glycol, a major ion suppressor.

366 Medial and lateral aspects of the joint were sectioned sagittally at 8 μ m thickness in a
367 cryostat set to -30°C (OTF5000 Cryostat, Bright Instrument Co Ltd, Tissue-Tek Accu-Edge 4689
368 blade). Because whole joints did not undergo formalin fixation or paraffin embedding, Cryofilm 3C
369 16 UF (SECTION-LAB, Hiroshima, Japan) was used to assist in transferring sections to indium
370 tin oxide (ITO) slides (Delta Technologies, CB-401N, 4-10 Ω /sq, 25 x 50 mm)[63]. Sections were
371 adhered to ITO slides using double-stick tape and then directly stored at -80°C until matrix
372 application.

373 **Matrix Application**

374 A sublimation apparatus (Chemglass Life Sciences, CG-3038) was used for matrix
375 application (Fig. S11). Sublimation was chosen over matrix spraying as it forms smaller, more
376 homogenous matrix crystals and lacks liquid—reducing the risk of molecule migration and
377 microcracks in marrow and bone[24]. 300 mg of 2,5-dihydroxybenzoic acid (DHB) (Alfa Aesar,
378 490-79-9) was uniformly dispersed in the base of the sublimation apparatus, ITO slides were
379 affixed to the flat bottom condenser, and the condenser was filled with tap water (22°C). The two
380 glass compartments of the sublimator were assembled using an O-ring seal and connected to a
381 vacuum pump. Tissue sections on ITO slides were sublimated at 50°C for 3 minutes under 68
382 mTorr vacuum, resulting in a uniform matrix layer (0.05 mg/cm²) that was then recrystallized in a
383 hydration chamber with 300 μ L of 5% methanol 0.1% formic acid spotted onto Whatman paper.
384 The chamber was heated in a 37°C oven for 1 minute, then ITO slides were sealed in the chamber
385 and heated at 37°C for 1 minute.

386 **MALDI Image Acquisition and Analysis**

387 A Bruker AutoFlex III MALDI Time-of-Flight (TOF) mass spectrometer (Bruker Daltonics)
388 equipped with a MTP Slide Adapter II Imaging Plate (Bruker Daltonics) was used for image
389 acquisition. Due to the size of the sublimator and ITO slides (25 x 50 mm), two small aluminum
390 slide trays were milled to fit ITO slides into the imaging plate. Using a Smartbeam Nd:YAG laser
391 (355 nm) and Bruker FlexImaging, images were collected in positive ionization and TOF modes
392 in the 50-1000 m/z mass range averaging 200 laser shots per pixel with a 100- μ m lateral
393 resolution (laser power = 30%, range = 90%, offset = 10%). Imaging data collected were analyzed
394 and ion images were generated using Bruker SCiLS lab.

395

396

397

398

399 **Acknowledgments**

400

401 **Funding:** Funding for the Montana State Mass Spectrometry Facility used in this
402 publication was made possible in part by the MJ Murdock Charitable Trust, the National
403 Institute of General Medical Sciences of the National Institutes of Health under Award
404 Numbers P20GM103474 and S10OD28650, and the MSU Office of Research and
405 Economic Development. This study was funded by the National Institutes of Health under
406 Award Numbers R01AR073964 and R01AR081489 (RKJ) and the National Science
407 Foundation under Award Number CMMI 1554708 (RKJ).

408

409 **Author contributions:**

410 Conceptualization: HDW, RKJ

411 Methodology: HDW, AHW, PB, DS, BB, RKJ

412 Investigation: HDW, AHW, DS

413 Visualization: HDW, AHW, DS

414 Supervision: DS, BB, RKJ

415 Writing—original draft: HDW, AHW

416 Writing—review & editing: HDW, AHW, PB, DS, BB, RKJ

417

418 **Competing interests:** Dr. June owns stock in Beartooth Biotech. Drs. June and
419 Brahmachary own stock in OpenBioWorks. Neither company was involved in this study.
420 Remaining authors have no conflicts of interest to disclose.

421

422 **Data and materials availability:** All data are available in the main text and the
423 supplementary materials. Raw metabolomics data is available in table S11.

424

425 **References**

426 [1] T.D. Brown, R.C. Johnston, C.L. Saltzman, J.L. Marsh, J.A. Buckwalter, Posttraumatic
427 osteoarthritis: a first estimate of incidence, prevalence, and burden of disease, *J Orthop Trauma*
428 20(10) (2006) 739-44.

429 [2] A.C. Thomas, T. Hubbard-Turner, E.A. Wikstrom, R.M. Palmieri-Smith, Epidemiology of
430 Posttraumatic Osteoarthritis, *J Athl Train* 52(6) (2017) 491-496.

431 [3] C.A. Gottlob, C.L. Baker, Jr., J.M. Pellissier, L. Colvin, Cost effectiveness of anterior cruciate
432 ligament reconstruction in young adults, *Clin Orthop Relat Res* (367) (1999) 272-82.

433 [4] L.Y. Griffin, M.J. Albohm, E.A. Arendt, R. Bahr, B.D. Beynon, M. Demaio, R.W. Dick, L.
434 Engebretsen, W.E. Garrett, Jr., J.A. Hannafin, T.E. Hewett, L.J. Huston, M.L. Ireland, R.J.
435 Johnson, S. Lephart, B.R. Mandelbaum, B.J. Mann, P.H. Marks, S.W. Marshall, G. Myklebust,
436 F.R. Noyes, C. Powers, C. Shields, Jr., S.J. Shultz, H. Silvers, J. Slauterbeck, D.C. Taylor, C.C.
437 Teitz, E.M. Wojtys, B. Yu, Understanding and preventing noncontact anterior cruciate ligament
438 injuries: a review of the Hunt Valley II meeting, January 2005, *Am J Sports Med* 34(9) (2006)
439 1512-32.

440 [5] L.S. Lohmander, P.M. Englund, L.L. Dahl, E.M. Roos, The long-term consequence of
441 anterior cruciate ligament and meniscus injuries: osteoarthritis, *Am J Sports Med* 35(10) (2007)
442 1756-69.

443 [6] M.E. Cinque, G.J. Dornan, J. Chahla, G. Moatshe, R.F. LaPrade, High Rates of
444 Osteoarthritis Develop After Anterior Cruciate Ligament Surgery: An Analysis of 4108 Patients,
445 *Am J Sports Med* 46(8) (2018) 2011-2019.

446 [7] D.N. Giugliano, J.L. Solomon, ACL tears in female athletes, *Phys Med Rehabil Clin N Am*
447 18(3) (2007) 417-38, viii.

- 448 [8] A.M. Bruder, A.G. Culvenor, M.G. King, M. Haberfield, E.A. Roughead, J. Mastwyk, J.L.
449 Kemp, M. Ferraz Pazzinatto, T.J. West, S.L. Coburn, S.M. Cowan, A.M. Ezzat, L. To, K.
450 Chilman, J.L. Couch, J.L. Whittaker, K.M. Crossley, Let's talk about sex (and gender) after ACL
451 injury: a systematic review and meta-analysis of self-reported activity and knee-related
452 outcomes, *Br J Sports Med* 57(10) (2023) 602-610.
- 453 [9] C.L. Blaker, D.M. Ashton, N. Doran, C.B. Little, E.C. Clarke, Sex- and injury-based
454 differences in knee biomechanics in mouse models of post-traumatic osteoarthritis, *J Biomech*
455 114 (2021) 110152.
- 456 [10] V.K. Srikanth, J.L. Fryer, G. Zhai, T.M. Winzenberg, D. Hosmer, G. Jones, A meta-analysis
457 of sex differences prevalence, incidence and severity of osteoarthritis, *Osteoarthritis Cartilage*
458 13(9) (2005) 769-81.
- 459 [11] S.C. Faber, F. Eckstein, S. Lukasz, R. Muhlbauer, J. Hohe, K.H. Englmeier, M. Reiser,
460 Gender differences in knee joint cartilage thickness, volume and articular surface areas:
461 assessment with quantitative three-dimensional MR imaging, *Skeletal Radiol* 30(3) (2001) 144-
462 50.
- 463 [12] K. Hitt, J.R. Shurman, 2nd, K. Greene, J. McCarthy, J. Moskal, T. Hoeman, M.A. Mont,
464 Anthropometric measurements of the human knee: correlation to the sizing of current knee
465 arthroplasty systems, *J Bone Joint Surg Am* 85-A Suppl 4 (2003) 115-22.
- 466 [13] B.D. Hislop, C. Devine, R.K. June, C.M. Heveran, Subchondral bone structure and synovial
467 fluid metabolism are altered in injured and contralateral limbs 7 days after non-invasive joint
468 injury in skeletally-mature C57BL/6 mice, *Osteoarthritis Cartilage* (2022).
- 469 [14] B. Mickiewicz, B.J. Heard, J.K. Chau, M. Chung, D.A. Hart, N.G. Shrive, C.B. Frank, H.J.
470 Vogel, Metabolic profiling of synovial fluid in a unilateral ovine model of anterior cruciate
471 ligament reconstruction of the knee suggests biomarkers for early osteoarthritis, *J Orthop Res*
472 33(1) (2015) 71-7.
- 473 [15] C.W. Wallace, B. Hislop, A.K. Hahn, A.E. Erdogan, P.P. Brahmachary, R.K. June,
474 Correlations between metabolites in the synovial fluid and serum: A mouse injury study, *J*
475 *Orthop Res* (2022).
- 476 [16] H.D. Welhaven, A.H. Welfley, P. Pershad, J. Satalich, R. O'Connell, B. Bothner, A.R. Vap,
477 R.K. June, Metabolic phenotypes reflect patient sex and injury status: A cross-sectional analysis
478 of human synovial fluid, *Osteoarthritis Cartilage* (2023).
- 479 [17] A.K. Hahn, C.W. Wallace, H.D. Welhaven, E. Brooks, M. McAlpine, B.A. Christiansen, S.T.
480 Walk, R.K. June, The microbiome mediates epiphyseal bone loss and metabolomic changes
481 after acute joint trauma in mice, *Osteoarthritis Cartilage* 29(6) (2021) 882-893.
- 482 [18] E.H. Seeley, R.M. Caprioli, Molecular imaging of proteins in tissues by mass spectrometry,
483 *Proc Natl Acad Sci U S A* 105(47) (2008) 18126-31.
- 484 [19] E.R. Amstalden van Hove, D.F. Smith, R.M. Heeren, A concise review of mass
485 spectrometry imaging, *J Chromatogr A* 1217(25) (2010) 3946-54.
- 486 [20] B. Cillero-Pastor, G.B. Eijkel, A. Kiss, F.J. Blanco, R.M. Heeren, Matrix-assisted laser
487 desorption ionization-imaging mass spectrometry: a new methodology to study human
488 osteoarthritic cartilage, *Arthritis Rheum* 65(3) (2013) 710-20.
- 489 [21] B. Cillero-Pastor, G. Eijkel, A. Kiss, F.J. Blanco, R.M. Heeren, Time-of-flight secondary ion
490 mass spectrometry-based molecular distribution distinguishing healthy and osteoarthritic human
491 cartilage, *Anal Chem* 84(21) (2012) 8909-16.
- 492 [22] M.J. Peffers, B. Cillero-Pastor, G.B. Eijkel, P.D. Clegg, R.M. Heeren, Matrix assisted laser
493 desorption ionization mass spectrometry imaging identifies markers of ageing and osteoarthritic
494 cartilage, *Arthritis Res Ther* 16(3) (2014) R110.
- 495 [23] B. Cillero-Pastor, G.B. Eijkel, F.J. Blanco, R.M. Heeren, Protein classification and
496 distribution in osteoarthritic human synovial tissue by matrix-assisted laser desorption ionization
497 mass spectrometry imaging, *Anal Bioanal Chem* 407(8) (2015) 2213-22.


- 498 [24] C.J. Good, E.K. Neumann, C.E. Butrico, J.E. Cassat, R.M. Caprioli, J.M. Spraggins, High
499 Spatial Resolution MALDI Imaging Mass Spectrometry of Fresh-Frozen Bone, *Anal Chem* 94(7)
500 (2022) 3165-3172.
- 501 [25] M. Yamauchi, M. Terajima, M. Shiiba, Lysine Hydroxylation and Cross-Linking of Collagen,
502 *Methods Mol Biol* 1934 (2019) 309-324.
- 503 [26] S. Pornprasertsuk, W.R. Duarte, Y. Mochida, M. Yamauchi, Overexpression of lysyl
504 hydroxylase-2b leads to defective collagen fibrillogenesis and matrix mineralization, *J Bone*
505 *Miner Res* 20(1) (2005) 81-7.
- 506 [27] M. Saito, K. Marumo, Collagen cross-links as a determinant of bone quality: a possible
507 explanation for bone fragility in aging, osteoporosis, and diabetes mellitus, *Osteoporos Int* 21(2)
508 (2010) 195-214.
- 509 [28] A.K. Carlson, R.A. Rawle, C.W. Wallace, E.G. Brooks, E. Adams, M.C. Greenwood, M.
510 Olmer, M.K. Lotz, B. Bothner, R.K. June, Characterization of synovial fluid metabolomic
511 phenotypes of cartilage morphological changes associated with osteoarthritis, *Osteoarthritis*
512 *Cartilage* 27(8) (2019) 1174-1184.
- 513 [29] K. Tootsi, K. Vilba, A. Martson, J. Kals, K. Paapstel, M. Zilmer, Metabolomic Signature of
514 Amino Acids, Biogenic Amines and Lipids in Blood Serum of Patients with Severe Osteoarthritis,
515 *Metabolites* 10(8) (2020).
- 516 [30] A. Ohnishi, T. Osaki, Y. Matahira, T. Tsuka, T. Imagawa, Y. Okamoto, S. Minami,
517 Correlation of plasma amino acid concentrations and chondroprotective effects of glucosamine
518 and fish collagen peptide on the development of osteoarthritis, *J Vet Med Sci* 75(4) (2013) 497-
519 502.
- 520 [31] Y. Hu, Q. Wu, Y. Qiao, P. Zhang, W. Dai, H. Tao, S. Chen, Disturbances in Metabolic
521 Pathways and the Identification of a Potential Biomarker Panel for Early Cartilage Degeneration
522 in a Rabbit Anterior Cruciate Ligament Transection Model, *Cartilage* 13(2_suppl) (2021) 1376S-
523 1387S.
- 524 [32] H.D. Welhaven, A.H. Welfley, P. Pershad, J. Satalich, R. O'Connell, B. Bothner, A.R. Vap,
525 R.K. June, Metabolic phenotypes reflect patient sex and injury status: A cross-sectional analysis
526 of human synovial fluid, *Osteoarthritis Cartilage* 32(9) (2024) 1074-1083.
- 527 [33] K.H. Ding, M. Cain, M. Davis, C. Bergson, M. McGee-Lawrence, C. Perkins, T. Hardigan, X.
528 Shi, Q. Zhong, J. Xu, W.B. Bollag, W. Hill, M. Elsalanty, M. Hunter, M.C. Isales, P. Lopez, M.
529 Hamrick, C.M. Isales, Amino acids as signaling molecules modulating bone turnover, *Bone* 115
530 (2018) 15-24.
- 531 [34] A.D. Conigrave, E.M. Brown, R. Rizzoli, Dietary protein and bone health: roles of amino
532 acid-sensing receptors in the control of calcium metabolism and bone homeostasis, *Annu Rev*
533 *Nutr* 28 (2008) 131-55.
- 534 [35] G. Yang, H. Zhang, T. Chen, W. Zhu, S. Ding, K. Xu, Z. Xu, Y. Guo, J. Zhang, Metabolic
535 analysis of osteoarthritis subchondral bone based on UPLC/Q-TOF-MS, *Anal Bioanal Chem*
536 408(16) (2016) 4275-86.
- 537 [36] T. Igari, M. Tsuchizawa, T. Shimamura, Alteration of tryptophan metabolism in the synovial
538 fluid of patients with rheumatoid arthritis and osteoarthritis, *Tohoku J Exp Med* 153(2) (1987) 79-
539 86.
- 540 [37] K.Y. Kang, S.H. Lee, S.M. Jung, S.H. Park, B.H. Jung, J.H. Ju, Downregulation of
541 Tryptophan-related Metabolomic Profile in Rheumatoid Arthritis Synovial Fluid, *J Rheumatol*
542 42(11) (2015) 2003-11.
- 543 [38] E.M. Leimer, L.M. Tanenbaum, D.L. Nettles, R.D. Bell, M.E. Easley, L.A. Setton, S.B.
544 Adams, Amino Acid Profile of Synovial Fluid Following Intra-articular Ankle Fracture, *Foot Ankle*
545 *Int* 39(10) (2018) 1169-1177.
- 546 [39] H. Akasaka, H. Yoshida, H. Takizawa, N. Hanawa, T. Tobisawa, M. Tanaka, N. Moniwa, N.
547 Togashi, T. Yamashita, S. Kuroda, N. Ura, T. Miura, B.-C. Investigators, The impact of elevation

- 548 of serum uric acid level on the natural history of glomerular filtration rate (GFR) and its sex
549 difference, *Nephrol Dial Transplant* 29(10) (2014) 1932-9.
- 550 [40] S.L. Mumford, S.S. Dasharathy, A.Z. Pollack, N.J. Perkins, D.R. Mattison, S.R. Cole, J.
551 Wactawski-Wende, E.F. Schisterman, Serum uric acid in relation to endogenous reproductive
552 hormones during the menstrual cycle: findings from the BioCycle study, *Hum Reprod* 28(7)
553 (2013) 1853-62.
- 554 [41] G.R. Steinberg, S.L. Macaulay, M.A. Febbraio, B.E. Kemp, AMP-activated protein kinase--
555 the fat controller of the energy railroad, *Can J Physiol Pharmacol* 84(7) (2006) 655-65.
- 556 [42] J. Wang, J. Li, D. Song, J. Ni, M. Ding, J. Huang, M. Yan, AMPK: implications in
557 osteoarthritis and therapeutic targets, *Am J Transl Res* 12(12) (2020) 7670-7681.
- 558 [43] D. Yi, H. Yu, K. Lu, C. Ruan, C. Ding, L. Tong, X. Zhao, D. Chen, AMPK Signaling in
559 Energy Control, Cartilage Biology, and Osteoarthritis, *Front Cell Dev Biol* 9 (2021) 696602.
- 560 [44] T. Purdom, L. Kravitz, K. Dokladny, C. Mermier, Understanding the factors that effect
561 maximal fat oxidation, *J Int Soc Sports Nutr* 15 (2018) 3.
- 562 [45] S. Yang, J. Wang, Estrogen Activates AMP-Activated Protein Kinase in Human Endothelial
563 Cells via ERbeta/Ca(2+)/Calmodulin-Dependent Protein Kinase Kinase beta Pathway, *Cell*
564 *Biochem Biophys* 72(3) (2015) 701-7.
- 565 [46] N. Cui, M. Hu, R.A. Khalil, Biochemical and Biological Attributes of Matrix
566 Metalloproteinases, *Prog Mol Biol Transl Sci* 147 (2017) 1-73.
- 567 [47] R. Visse, H. Nagase, Matrix metalloproteinases and tissue inhibitors of metalloproteinases:
568 structure, function, and biochemistry, *Circ Res* 92(8) (2003) 827-39.
- 569 [48] R.P. Verma, C. Hansch, Matrix metalloproteinases (MMPs): chemical-biological functions
570 and (Q)SARs, *Bioorg Med Chem* 15(6) (2007) 2223-68.
- 571 [49] Y.J. Lee, E.B. Lee, Y.E. Kwon, J.J. Lee, W.S. Cho, H.A. Kim, Y.W. Song, Effect of estrogen
572 on the expression of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 and tissue
573 inhibitor of metalloproteinase-1 in osteoarthritis chondrocytes, *Rheumatol Int* 23(6) (2003) 282-
574 8.
- 575 [50] A.K. Carlson, R.A. Rawle, E. Adams, M.C. Greenwood, B. Bothner, R.K. June, Application
576 of global metabolomic profiling of synovial fluid for osteoarthritis biomarkers, *Biochem Biophys*
577 *Res Commun* 499(2) (2018) 182-188.
- 578 [51] M.R. Eveque-Mourroux, P.J. Emans, A. Boonen, B.S.R. Claes, F.G. Bouwman, R.M.A.
579 Heeren, B. Cillero-Pastor, Heterogeneity of Lipid and Protein Cartilage Profiles Associated with
580 Human Osteoarthritis with or without Type 2 Diabetes Mellitus, *J Proteome Res* 20(5) (2021)
581 2973-2982.
- 582 [52] P. Pousinis, P.R.W. Gowler, J.J. Burston, C.A. Ortori, V. Chapman, D.A. Barrett, Lipidomic
583 identification of plasma lipids associated with pain behaviour and pathology in a mouse model of
584 osteoarthritis, *Metabolomics* 16(3) (2020) 32.
- 585 [53] A.K. Carlson, R.A. Rawle, C.W. Wallace, E. Adams, M.C. Greenwood, B. Bothner, R.K.
586 June, Global metabolomic profiling of human synovial fluid for rheumatoid arthritis biomarkers,
587 *Clin Exp Rheumatol* 37(3) (2019) 393-399.
- 588 [54] H.D. Welhaven, E. Viles, J. Starke, C. Wallace, B. Bothner, R.K. June, A.K. Hahn,
589 Metabolomic profiles of cartilage and bone reflect tissue type, radiography-confirmed
590 osteoarthritis, and spatial location within the joint, *Biochem Biophys Res Commun* 703 (2024)
591 149683.
- 592 [55] H.D. Welhaven, A.H. Welfley, P. Brahmachary, A.R. Bergstrom, E. Houske, M. Glimm, B.
593 Bothner, A.K. Hahn, R.K. June, Metabolomic Profiles and Pathways in Osteoarthritic Human
594 Cartilage: A Comparative Analysis with Healthy Cartilage, *Metabolites* 14(4) (2024).
- 595 [56] B.A. Christiansen, M.J. Anderson, C.A. Lee, J.C. Williams, J.H. Yik, D.R. Haudenschild,
596 Musculoskeletal changes following non-invasive knee injury using a novel mouse model of post-
597 traumatic osteoarthritis, *Osteoarthritis Cartilage* 20(7) (2012) 773-82.


- 598 [57] B.A. Christiansen, F. Guilak, K.A. Lockwood, S.A. Olson, A.A. Pitsillides, L.J. Sandell, M.J.
599 Silva, M.C. van der Meulen, D.R. Haudenschild, Non-invasive mouse models of post-traumatic
600 osteoarthritis, *Osteoarthritis Cartilage* 23(10) (2015) 1627-38.
- 601 [58] C.B. Little, D.J. Hunter, Post-traumatic osteoarthritis: from mouse models to clinical trials,
602 *Nat Rev Rheumatol* 9(8) (2013) 485-97.
- 603 [59] C.W. Wallace, B. Hislop, A.K. Hahn, A.E. Erdogan, P.P. Brahmachary, R.K. June,
604 Correlations between metabolites in the synovial fluid and serum: A mouse injury study, *J*
605 *Orthop Res* 40(12) (2022) 2792-2802.
- 606 [60] D.R. Seifer, B.D. Furman, F. Guilak, S.A. Olson, S.C. Brooks, 3rd, V.B. Kraus, Novel
607 synovial fluid recovery method allows for quantification of a marker of arthritis in mice,
608 *Osteoarthritis Cartilage* 16(12) (2008) 1532-8.
- 609 [61] Z. Pang, G. Zhou, J. Ewald, L. Chang, O. Hacariz, N. Basu, J. Xia, Using MetaboAnalyst
610 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global
611 metabolomics data, *Nat Protoc* 17(8) (2022) 1735-1761.
- 612 [62] K.A. Nelson, G.J. Daniels, J.W. Fournie, M.J. Hemmer, Optimization of whole-body
613 zebrafish sectioning methods for mass spectrometry imaging, *J Biomol Tech* 24(3) (2013) 119-
614 27.
- 615 [63] T. Kawamoto, K. Kawamoto, Preparation of thin frozen sections from nonfixed and
616 undecalcified hard tissues using Kawamoto's film method (2012), *Methods Mol Biol* 1130 (2014)
617 149-164.
- 618
619
620

621
622

Figures




623
624 **Figure 1. Global metabolomic profiles of whole joints, synovial fluid, and serum are driven**
625 **by injury status.** (A-C) Partial Least Squares-Discriminant Analysis (PLS-DA) finds some overlap
626 between injured and naïve whole joint and synovial fluid and near-perfect separation of injured
627 and naïve serum. (D-F) Fold change analysis distinguished populations of metabolite features
628 driving separation of metabolomic profiles. (D) Specifically, 250 and 291 metabolite features were
629 highest in injured and naïve whole joints, respectively. (E) 373 and 155 metabolite features were
630 highest in injured and naïve synovial fluid, respectively. (F) 386 and 195 features were highest in
631 injured and naïve serum, respectively. Similarly, PLS-DA reveals overlap between injured,
632 contralateral, and naïve (G) whole joints and (H) synovial fluid with injured samples clustering
633 together between contralateral and naïve samples. To pinpoint pathways driving metabolomic
634 differences between limbs with different injury statuses, median intensity heatmap analyses
635 where injured and contralateral limbs were normalized to naïve limbs were performed. Clusters
636 of co-regulated metabolite features within (I) whole joint and (J) synovial fluid samples were
637 subjected to pathway analyses to identify biological pathways that differ in regulation across limbs
638 in both whole joint and synovial fluid samples. Combined, data provide strong evidence of distinct
639 metabolomic regulation associated with injury status. Columns represent limbs (naïve, injured,
640 contralateral) and rows represent metabolite features. Cooler and warmer colors indicate lower
641 and higher metabolite abundance relative to the mean, respectively. The colors in A-J correspond
642 to: purple = naïve, orange = injured, green = contralateral whole joint; sample types - red = whole
643 joint, blue = synovial fluid, yellow = serum.



644
645
646
647

Figure 2. Metabolomic profiles of whole joint, synovial fluid, and serum show sexual dimorphism across injured and naive mice. (A-C) Partial Least Squares-Discriminant Analysis (PLS-DA) finds (A) complete separation of injured whole joints from males and females and


648 minimal overlap when comparing (B) female and (C) male injured and naïve mice. (D-F) Fold
649 change analysis distinguished populations of whole-joint derived metabolite features driving
650 separation of metabolomic profiles. (G-I) PLS-DA finds minimal overlap when comparing (G)
651 injured SF from males and females, (H) female and (I) male injured and naïve mice. (J-L) Fold
652 change analysis identified populations of synovial fluid metabolite features contributing to the
653 separation of mice that differ by sex and injury. (M-O) PLS-DA finds clear separation with no
654 overlap when comparing (M) injured SF from males and females, (N) female and (O) male injured
655 and naïve mice. (P-R) Fold change analysis identified populations of metabolite features driving
656 separation of serum metabolomic profiles. The colors in A-R correspond to: pink = injured
657 females, peach = naïve females, royal blue = injured males, light blue = naïve males. sample
658 types - red = whole joint, blue = synovial fluid, yellow = serum.
659
660



661
662
663
664
665
666
667
668


Figure 3. MALDI-MSI combined ion images from sagittal whole joint sections. Heatmap analysis of putatively identified molecular species across various tissue structures. Spatial resolution = 100 μm . Scale bar = 1 mm. Interval width = 0.35 Da. Colors in panels from left to right: L-carnitine (162.29 m/z, purple), $\text{C}_{36}\text{H}_{38}\text{O}_7$ (629.61 m/z, orange), (820.41 m/z, blue), hydroxypropyl-isoleucine (245.10 m/z, yellow), and lipid species 18:2/16:0 (758.57 m/z, pink).

669 **Supplemental Figures**




670
671 **Figure S1. The metabolome is distinct for whole joints, synovial fluid, and serum.** Partial
672 Least Squares-Discriminant Analysis (PLS-DA) of (A) all samples and (B) only samples from
673 injured mice displays clear separation of whole joints, synovial fluid, and serum suggesting the
674 metabolome of each tissue is substantially distinct from others. (C) ANOVA analysis identified
675 2,264 metabolite features that were significantly dysregulated across samples from all three tissue
676 types. (D) When comparing samples from injured mice only, ANOVA analysis identified 1,891
677 significantly dysregulated features across tissue types. Colors in A-B correspond to: red = whole
678 joint, blue = synovial fluid, yellow = serum.

679
680



681
682 **Figure S2. Volcano plot analysis reveals injury-associated metabolites.** (A-C) To further
683 examine metabolic differences associated with injury status across tissue types, volcano plot
684 analysis was performed and identified numerous metabolite features that had a fold change > 2,
685 a p-value < 0.05, and were differentially regulated between injured and naïve whole joints (A, n =
686 70, red), synovial fluid (B, n = 131, blue), and serum (C, n = 26, yellow).

687
688



689
690 **Figure S3. Whole joint metabolome differs by sex and injury.** (A-C) Partial Least Squares-
691 Discriminant Analysis (PLS-DA) finds (A) complete separation of injured whole joints from males
692 and females and minimal overlap when comparing (B) female and (C) male injured and naïve
693 mice. (D-F) Fold change analysis distinguished populations of metabolite features driving
694 separation of metabolomic profiles. (D) Specifically, 315 and 314 metabolite features were highest
695 in injured females and males, respectively. (E) 509 and 319 metabolite features were highest in
696 injured females and naïve females, respectively. (F) 242 and 288 features were highest in injured
697 males and naïve males, respectively. (G-I) To further examine metabolic differences associated
698 with injury and sex, volcano plot analysis was performed and identified numerous metabolite
699 features that had a fold change > 2, a p-value < 0.05, and were differentially regulated between
700 injured males and females (G, n = 110), injured and naïve females (H, n = 158), and injured and
701 naïve males (I, n = 32). The colors in A-I correspond to: pink = injured females, peach = naïve
702 females, royal blue = injured males, light blue = naïve males.

703
704
705
706
707





Figure S4. Synovial fluid metabolome differs across injured, contralateral, and naïve limbs.

(A-C) Partial Least Squares-Discriminant Analysis (PLS-DA) finds some overlap between (A) injured and naïve, (B) naïve and contralateral, and (C) injured and contralateral synovial fluid. (D-F) Fold change analysis distinguished populations of metabolite features driving separation of metabolomic profiles. (D) Specifically, 318 and 253 metabolite features were highest in injured and naïve synovial fluid, respectively. (E) 269 and 178 metabolite features were highest in contralateral and naïve synovial fluid, respectively. (F) 303 and 291 features were highest in contralateral and injured synovial fluid, respectively. (G-I) To further examine metabolic differences associated with injury status across whole joints, volcano plot analysis was performed and identified numerous metabolite features that had a fold change > 2, a p-value < 0.05, and were differentially regulated between injured and naïve (G, n = 59), contralateral and naïve (H, n = 81), and contralateral and injured synovial fluid (I, n = 140). The colors in A-I correspond to: purple = naïve synovial fluid, orange = injured synovial fluid, green = contralateral synovial fluid.

708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723

724



725

726

727

728

729

730

731

732

733

734

735

736

737

738

739


740

741

742

743

Figure S5. Sexual dimorphic patterns are detected across whole joints, synovial fluid, and serum from injured and naïve mice. (A-C) Partial Least Squares-Discriminant Analysis (PLS-DA) finds (A) minimal overlap of male and female whole joints, while (B) synovial fluid and (C) serum from males and females perfectly clusters apart from each other. (D-F) Fold change analysis distinguished populations of metabolite features driving separation of male and female metabolomic profiles. (D) Specifically, 253 and 314 metabolite features were highest in female and male whole joints, respectively. (E) 334 and 137 metabolite features were highest in female and male synovial fluid, respectively. (F) 267 and 315 features were highest in female and male serum, respectively. (G-I) To further examine metabolic differences associated with sex across tissue types, volcano plot analysis was performed and identified numerous metabolite features that had a fold change > 2, a p-value < 0.05, and were differentially regulated between male and female whole joints (G, n = 90), synovial fluid (H, n = 159), and serum (I, n = 63). The colors in A-I correspond to: pink = females, blue = males, red = whole joint, blue = synovial fluid, yellow = serum.



744

745

746

747

748

749

750

751

752

753

754

755


756

757

758


759

Figure S6. Volcano plot analysis reveals both sex- and injury-associated metabolites across sample types. (A-C) To pinpoint metabolic differences associated with injury and sex at the whole joint level, volcano plot analysis was performed and identified numerous metabolite features that had a fold change > 2, a p-value < 0.05, and were differentially regulated between injured males and females (A, n = 110), injured and naïve females (B, n = 158), and injured and naïve males (C, n = 32). (D-F) Among SF samples, volcano plot analysis identified metabolites that were differentially regulated between injured males and females (D, n = 95), injured and naïve females (E, n = 101), and injured and naïve males (F, n = 99). (G-I) At the serum level, a similar pattern was found where volcano plot analysis identified metabolites among injured males and females (G, n = 82), injured and naïve females (H, n = 92), and injured and naïve males (I, n = 87). The colors in A-I correspond to: pink = injured females, peach = naïve females, royal blue = injured males, light blue = naïve males, red = whole joint, blue = synovial fluid, yellow = serum.




760
761 **Figure S7. MALDI-MSI analysis combined with LC-MS/MS detects and identifies differences**
762 **in osteochondral metabolites.** (A) Molecular species that were putatively identified with notable
763 spatial patterns amongst bone and the growth plate include alpha-carboxy-delta-decalactone
764 (215.20, green), hydroxyprolyl-isoleucine (245.11 m/z, yellow), and $C_{36}H_{38}O_7$ (629.61 m/z,
765 orange). (B) conversely, molecular species that were putatively identified with notable patterns
766 among bone marrow regions include L-carnitine (162.29 m/z, purple) and various lipid species
767 (34 carbons, 2 double bonds – 758.57 m/z, pink; 34 carbons, 3 double bonds – 778.59 m/z,
768 teal; 39 carbons, 6 double bonds – 820.41 m/z, blue). Spatial resolution = 100 μ m. Scale bar = 1
769 mm. Interval width = 0.35 Da.

770




771
772
773
774
775
776
777
778

Figure S8. Unidentified molecular species localize to different structures within the joint. Species more abundant in bone and growth plate included 369.03 m/z (pink), 560.67 m/z (red), and 598.66 m/z (light blue). Conversely, those more abundant in bone marrow included 803.96 m/z (dark blue), 609.13 m/z (cyan), and 710.99 m/z (light pink). Spatial resolution = 100 μ m. Scale bar = 1 mm. Interval width = 0.35 Da.




779
780 **Figure S9. Injury-associated spatial distribution patterns between injury and contralateral**
781 **limbs.** (A) 544.41 m/z and (B) putatively identified PC(14:0/22:6) (878.54 m/z) display notable
782 injury associated patterns between medial and lateral sagittal sections from an injured and
783 contralateral joint. Left to right – left lateral, left medial, right medial, right lateral. Spatial resolution
784 = 100 μ m. Scale bar = 1 mm. Interval width = 0.35 Da.
785
786



787
788
789
790
791
792
793
794
795
796

Figure S10. MALDI-MSI experimental workflow to spatially image osteochondral metabolites. Whole joints were obtained from C57Bl6/J male and female injured and naïve mice, embedded in 5% carboxymethylcellulose (CMC)/10% gelatin, sectioned (8 μm), transferred to indium tin oxide (ITO) slides, and sublimed with 2,5-dihydroxybenzoic acid matrix. Data were then acquired using 2D laser scanning followed by reconstruction of intensity images representing m/z values and intensity.



797
798
799
800
801

Figure S11. Sublimation apparatus used to uniformly coat whole joints with matrix. Components of the sublimation apparatus include the cold finger, hot plate, glass condenser and sleeve, O-ring seal, and vacuum pump (not pictured).

802 **Supplemental Table Legends**

803

804 **Table S1.** Metabolic pathways detected in naïve and injured (A) whole joints, (B) synovial fluid,
805 and (C) serum. All pathways listed were false discovery rate (FDR)-corrected using the Benjamini-
806 Hochberg method.

807

808 **Table S2.** Liquid chromatography tandem mass spectrometry (LC-MS/MS).derived putative
809 metabolite identifications that differ between male and female injured mice across tissues (serum,
810 synovial fluid, whole joints), and limbs (injured, contralateral, naïve). Provided information for
811 putative identifications includes observed and theoretical mass-to-charge ratios (m/z), parts per
812 million (ppm) error, compound identification, accepted description/name, adduct information,
813 chemical formula, and scores (total, fragmentation). Identifications with an error > 10 ppm, overall
814 score < 65, and fragmentation score < 30 were excluded.

815

816 **Table S3.** Metabolic pathways associated with injured, contralateral, and naïve whole joints
817 identified by median metabolite intensity heatmap analysis. Clusters defined in Figure S3B. All
818 pathways listed were false discovery rate (FDR)-corrected using the Benjamini-Hochberg
819 method.

820

821 **Table S4.** Metabolic pathways associated with injured, contralateral, and naïve synovial fluid
822 identified by median metabolite intensity heatmap analysis. Clusters defined in Figure S3D. All
823 pathways listed were false discovery rate (FDR)-corrected using the Benjamini-Hochberg
824 method.

825

826 **Table S5.** Differentially regulated pathways, identified by MetaboAnalyst, when comparing
827 injured, contralateral, and naïve whole joints using fold change analysis.

828

829 **Table S6.** Differentially regulated pathways, identified by MetaboAnalyst, when comparing
830 synovial fluid from injured, contralateral, and naïve limbs using fold change analysis.

831

832 **Table S7.** Differentially regulated pathways, identified by MetaboAnalyst, when comparing whole
833 joints obtained from male and female injured and naïve mice using fold change analysis.

834

835 **Table S8.** Differentially regulated pathways, identified by MetaboAnalyst, when comparing
836 synovial fluid from male and female injured and naïve mice using fold change analysis.

837

838 **Table S8.** Differentially regulated pathways, identified by MetaboAnalyst, when comparing serum
839 from male and female injured and naïve mice using fold change analysis.

840

841 **Table S10.** MALDI ion data.

842

843 **Table S11.** Raw metabolomics output.